HR Alert: CA 1102.5 Whistleblower Claim Defeated by Years of Performance Records

For HR leaders, Han v. Pfizer is a stark reminder that the most effective shield against retaliation claims isn't just a strong anti-retaliation policy—it's the everyday discipline of performance documentation. When a compliance analytics employee at Pfizer reported suspected illegal activity and later faced termination, the company's multi-year paper trail of underperformance became the difference between liability and a complete win at summary judgment. This case offers a concrete template for building defensible HR processes in high-risk jurisdictions.

The U.S. District Court for the Northern District of California handed down a significant employment law decision in Han v. Pfizer (No. 23-cv-039080-AMO), granting summary judgment to pharmaceutical giant Pfizer in a whistleblower retaliation lawsuit. This ruling, issued in early July 2026, underscores a vital lesson for employers: while California courts continue to construe protected activity broadly under Labor Code section 1102.5, an employer's right to terminate for legitimate, documented performance reasons remains robust—even when the employee engaged in protected whistleblowing.

“

District Court for the Northern District of California handed down a significant employment law decision in Han v.

The plaintiff, a compliance analytics employee, internally reported suspected illegal activity and later reiterated those concerns while pushing back against a notice of underperformance from his supervisor. Pfizer ultimately terminated him, citing performance-related issues. He sued under Section 1102.5 and related state law claims, alleging retaliatory discharge. In evaluating Pfizer's summary judgment motion, the court first rejected the argument that no protected activity occurred simply because identifying compliance risks was part of the plaintiff's job description. This aligns with a growing body of California precedent interpreting protected activity expansively, often encompassing even routine job duties if they involve reporting legal violations. However, the court then pivoted to the employer's proof that it would have made the same termination decision regardless of the whistleblowing.

Pfizer's defense rested on years of contemporaneously documented performance deficiencies that predated any protected reports. The record included multiple performance evaluations and corroborating criticisms showing repeated, consistent underperformance feedback. This evidentiary foundation was enough to defeat the causation requirement of the Section 1102.5 claim. The court thus granted summary judgment, finding no triable issue as to whether retaliation was a substantial motivating factor.

For employers, Han reinforces a dual message: assume that internal complaints about legal or regulatory matters will be deemed protected under California's slacker standard, but also recognize that rigorous, consistently maintained performance documentation can be the decisive shield. The decision does not change the broad interpretation of protected activity, but it illustrates the power of the 'same decision' defense—where evidence shows termination would have happened for legitimate reasons anyway, the retaliation claim fails.